Skip to main content
. 2021 Mar 4;9(4):2259–2263. doi: 10.1002/ccr3.4008

FIGURE 4.

FIGURE 4

Contrast‐enhanced computed tomography (CT) revealed a primary tumor (black arrow) before the initiation of pembrolizumab (A). After three cycles of pembrolizumab, the primary tumor showed a 32% reduction (B). After 14 cycles, the primary tumor showed a 79% reduction (C)